je.st
news
Omeros Corporation: Q3 Revenue Miss Says Little About Omidria's Growth
2015-11-14 16:36:29| Biotech - Topix.net
Reimbursement the largest impediment to growth, but the company will resolve most of the issues with its new OMIDRIAssure program. Omeros' Q3 report was initially disappointing.
Tags: corporation
miss
growth
revenue
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||